Stephens Investment Management Group LLC Has $69.85 Million Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Stephens Investment Management Group LLC trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,351,331 shares of the specialty pharmaceutical company’s stock after selling 55,191 shares during the period. Stephens Investment Management Group LLC owned about 2.35% of Supernus Pharmaceuticals worth $69,850,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Jefferies Financial Group Inc. lifted its position in Supernus Pharmaceuticals by 62.0% in the 3rd quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock valued at $4,118,000 after acquiring an additional 32,979 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Supernus Pharmaceuticals during the 3rd quarter worth approximately $1,434,000. Phocas Financial Corp. bought a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $4,042,000. Westover Capital Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $1,587,000. Finally, Aberdeen Group plc bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $13,497,000.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $48.05 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $31.35 and a fifty-two week high of $59.68. The firm has a 50-day moving average of $47.18 and a 200 day moving average of $49.50. The firm has a market cap of $2.79 billion, a P/E ratio of -94.22, a PEG ratio of 1.03 and a beta of 0.54.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.